FDA Internal Review To Evaluate Potential Symlin Dosing Confusion
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency evaluation follows a medication safety alert for the adjunctive diabetes therapy issued by the Institute for Safe Medication Practices. Watchdog group cites confusion in dosage instructions that could result in overdose/underdose of Symlin.
You may also be interested in...
Amylin’s SymlinPen To Launch In December
Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."
Amylin’s SymlinPen To Launch In December
Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."
Symlin Approval For Type 1 Diabetes Less Risky Than Potential Off-Label Use, FDA Says
Off-label use for type 1 diabetes could endanger patients due to higher risk of severe hypoglycemia in type 1 disease if pramlintide were approved only for type 2 diabetes, FDA review documents show. Lengthy NDA review illustrates difficulty of designing trials in the context of insulin use, where benefit is tied to risk.